最多等待 10 秒，若超时请稍后重试。
Ben Kirk, Peggy M Cawthon, Hidenori Arai, José A Ávila-Funes, Rocco Barazzoni, Shalender Bhasin, Ellen F Binder, Olivier Bruyere, Tommy Cederholm, Liang-Kung Chen, Cyrus Cooper, Gustavo Duque, Roger A Fielding, Jack Guralnik, Douglas P Kiel, Francesco Landi, Jean-Yves Reginster, Avan A Sayer, Marjolein Visser, Stephan von Haehling, Jean Woo, Alfonso J Cruz-Jentoft
Department of Medicine, Western Health, Melbourne Medical School, University of Melbourne, Melbourne, VIC, Australia.
Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, Melbourne, VIC, Australia.
Age Ageing. 2024 Mar 1;53(3). doi: 10.1093/ageing/afae052.
Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists.
The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia.
The GLIS steering committee was formed in 2019-21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70-80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached.
107 participants (mean age: 54 ± 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on 'general aspects of sarcopenia' (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on 'components of sarcopenia' (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on 'outcomes of sarcopenia' (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as 'components of sarcopenia', whereas impaired physical performance was accepted as an 'outcome' rather than a 'component' of sarcopenia.
The GLIS has created the first global conceptual definition of sarcopenia, which will now serve to develop an operational definition for clinical and research settings.
肌肉减少症，即与年龄相关的肌肉质量和力量/功能丧失，是一种重要的临床病症。然而，目前尚无关于其定义的国际共识。
全球肌肉减少症领导倡议（GLIS）旨在通过建立肌肉减少症的全球概念定义来解决这一问题。
GLIS 指导委员会于 2019-2021 年成立，成员来自全球各地的相关科学学会。在此期间，指导委员会就该主题制定了一系列声明，并邀请来自这些学会的成员参加了两阶段的国际德尔菲研究。在 2022 年至 2023 年期间，参与者使用在线调查工具（SurveyMonkey）对一组声明的同意程度进行了排名。声明根据预设阈值进行分类：强烈同意（>80%）、中度同意（70-80%）和低度同意（<70%）。强烈同意的声明被接受，低度同意的声明被拒绝，中度同意的声明被重新引入，直到达成共识。
来自七大洲/地区 29 个国家的 107 名参与者（平均年龄：54±12 岁[1 名参与者年龄缺失]，64%为男性）完成了德尔菲调查。有 20 项声明被认为具有强烈的一致性。其中包括 6 项关于“肌肉减少症的一般方面”的声明（肌肉减少症的患病率随年龄增长而增加（98.3%）），3 项关于“肌肉减少症的组成部分”的声明（肌肉质量、肌肉力量和肌肉特异性力量都应成为肌肉减少症概念定义的一部分），以及 11 项关于“肌肉减少症的结果”的声明（肌肉减少症增加了身体机能受损的风险（97.9%））。德尔菲调查的一个关键发现是，肌肉质量、肌肉力量和肌肉特异性力量都被接受为“肌肉减少症的组成部分”，而身体机能受损被接受为“肌肉减少症的结果”，而非“组成部分”。
GLIS 制定了第一个全球肌肉减少症的概念定义，该定义将用于为临床和研究环境制定操作性定义。
